cilostazol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 86 Diseases   33 Trials   33 Trials   1472 News 


«12...678910111213141516...1718»
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Clinical, Journal, Heterogeneity:  Heterogeneous and dynamic lumen remodeling of the entire infrainguinal vein bypass grafts in patients. (Pubmed Central) -  Sep 16, 2020   
    It is found that remodeling that produces some critical minimum area or maximal percent reduction during the first postoperative month may predispose to vein graft failure. These findings offer insight into further investigation to examine the underlying mechanisms and opportunities to improve graft remodeling and durability.
  • ||||||||||  Xarelto (rivaroxaban) / J&J, Bayer, Pletal (cilostazol) / Otsuka
    [VIRTUAL] Inflammatory Bowel Disease in a Patient With Recurrent Arterial Thrombi With Resolution After Colectomy () -  Sep 15, 2020 - Abstract #ACG2020ACG_2329;    
    She was started on mesalamine suppositories and prednisone for presumed IBD...Post-colectomy, she had no further thrombi development and was discharged home on LMWH with transition to rivaroxaban, low-dose aspirin, and cilostazol...Only two prior case reports link colectomy to resolution of thrombi. In our case, it is difficult to establish causality, but the failure of anticoagulation with resolution of thrombi after colectomy raises the inquiry.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Actemra IV (tocilizumab) / Roche, JW Pharma
    [VIRTUAL] Recurrent Lower Gastrointestinal Bleed From Tocilizumab and High Dose Prednisone in a Patient With Takayasu Arthritis: A Case Report () -  Sep 15, 2020 - Abstract #ACG2020ACG_1942;    
    He has remained stable for the last 11 months, on infliximab and this dose of prednisone with the most recent Hb of 16.1...But there is little data regarding complications from tocilizumab in patients with TA. Here, we see a patient on tocilizumab and high dose steroids, who presented with lower GI track ulcers with hematochezia, who developed colonic ulcers that resolved when the medication was discontinued and the steroids tapered down to levels below 7.5 mg daily, like RA patients.
  • ||||||||||  Review, Journal:  Pharmacological treatment for Buerger's disease. (Pubmed Central) -  Sep 13, 2020   
    Very low-certainty evidence suggests there is no clear difference in pain scores and amputation rates between folic acid and placebo, in people with Buerger's disease and hyperhomocysteinaemia. Further well designed RCTs assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger's disease are needed.
  • ||||||||||  cilostazol / Generic mfg.
    Trial primary completion date:  A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID) (clinicaltrials.gov) -  Sep 10, 2020   
    P2,  N=200, Active, not recruiting, 
    Further well designed RCTs assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger's disease are needed. Trial primary completion date: Mar 2020 --> Aug 2020
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Clinical, Journal:  Outcomes and safety of electronic consult use in vascular surgery. (Pubmed Central) -  Sep 8, 2020   
    Within the Veterans Affairs vascular surgery service, eConsults provide a safe and effective means of triaging and providing recommendations for patients with vascular disease. eConsults used to augment traditional consultations may provide an important means of reducing clinic congestion for providers and reducing time and cost for patients.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Preclinical, Journal, IO Biomarker:  Gastroprotective effect of cilostazol against ethanol- and pylorus ligation-induced gastric lesions in rats. (Pubmed Central) -  Aug 29, 2020   
    Cilostazol, in a dose-dependent effect, exhibited vasodilatory, anti-inflammatory, and antiapoptotic actions in the gastric mucosa resulting in significant antiulcer activity comparable with the standard drug, ranitidine, but devoid of antisecretory activity. Therefore, its use should be dose and ulcer-inducer dependent.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Cilostazol ameliorates diabetic nephropathy by inhibiting highglucose- induced apoptosis. (Pubmed Central) -  Aug 26, 2020   
    In high-glucose-treated mesangial cells, CTZ reduced ROS production, altered the apoptotic status, and down-regulated transforming growth factor beta (TGF-β) and nuclear factor kappa light chain enhancer of activated B cells (NF-κB). Base on the results of our previous and current studies, CTZ deceleration of hyperglycemia-induced DN is attributable to ROS reduction and thereby maintenance of the mitochondrial function and reduction in TGF-β and NF-κB levels.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Clinical, Journal:  Reduced deformability contributes to impaired deoxygenation-induced ATP release from red blood cells of older adult humans. (Pubmed Central) -  Aug 23, 2020   
    In contrast, treating RBCs with a phosphodiesterase 3 inhibitor did not affect ATP release in either age group, possibly due to intact intracellular signalling downstream of deoxygenation as indicated by preserved cAMP and ATP release responses to pharmacological G protein activation in RBCs from older adults. These findings are the first to demonstrate that the age-related decrease in RBC deformability is a primary mechanism of impaired deoxygenation-induced ATP release, which may have implications for treating impaired vascular control with advancing age.
  • ||||||||||  Trial completion:  OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial (clinicaltrials.gov) -  Aug 19, 2020   
    P4,  N=1724, Completed, 
    These findings are the first to demonstrate that the age-related decrease in RBC deformability is a primary mechanism of impaired deoxygenation-induced ATP release, which may have implications for treating impaired vascular control with advancing age. Recruiting --> Completed
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Preparation of Hot-Melt Extruded Dosage Form for Enhancing Drugs Absorption Based on Computational Simulation. (Pubmed Central) -  Aug 17, 2020   
    Based on the PSA analysis, the surfactant induction was a crucial factor in cilostazol absorption; thus, an extrudate with an even distribution of lipids was produced using hot-melt extrusion technology, for inducing the bile salts in the gastrointestinal tract. In vivo experiments with rats demonstrated that the optimized hot-melt extruded formulation was absorbed more rapidly with lower deviation and regardless of the meal consumed when compared to marketed cilostazol formulations.
  • ||||||||||  Trial completion date, Trial primary completion date:  Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm (clinicaltrials.gov) -  Aug 8, 2020   
    P4,  N=198, Recruiting, 
    In vivo experiments with rats demonstrated that the optimized hot-melt extruded formulation was absorbed more rapidly with lower deviation and regardless of the meal consumed when compared to marketed cilostazol formulations. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Impact of IVUS-Derived Vessel Size on Midterm Outcomes After Stent Implantation in Femoropopliteal Lesions. (Pubmed Central) -  Jul 21, 2020   
    Multivariable analysis revealed that longer lesion length (OR 0.89, 95% CI 0.82 to 0.97, p29.0 mm vs 53.1% (95% CI 42.9% to 63.3%) in those with a distal EEM area ≤29.0 mm (p<0.001). In FP lesions with a larger distal vessel area estimated with IVUS, stent implantation can be considered as a reasonable treatment option, with the likelihood of acceptable midterm results.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    [VIRTUAL] PLATELET AGGREGATION TEST IN PATIENTS WHO RECEIVED GASTRIC ESD UNDER CONTINUOUS ANTIPLATELET AGENTS (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_4190;    
    Aims & Between April 2013 and March 2019, a total of 75 cases were performed gastric ESD and assessed by the aggregometer (PRP313 M, TAIYO Inc.) before procedures under continuous antiplatelet agents such as thienopyridine, aspirin, or cilostazol. The levels of platelet aggregometry is low in the cases taking thienopyridine or dual antiplatelet therapy, and the risk of post-ESD bleeding in patients under continuous antiplatelet agents might be assessed by platelet aggregation test.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    [VIRTUAL] PLATELET AGGREGATION TEST IN PATIENTS WHO RECEIVED GASTRIC ESD UNDER CONTINUOUS ANTIPLATELET AGENTS (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_2214;    
    Aims & Between April 2013 and March 2019, a total of 75 cases were performed gastric ESD and assessed by the aggregometer (PRP313 M, TAIYO Inc.) before procedures under continuous antiplatelet agents such as thienopyridine, aspirin, or cilostazol. The levels of platelet aggregometry is low in the cases taking thienopyridine or dual antiplatelet therapy, and the risk of post-ESD bleeding in patients under continuous antiplatelet agents might be assessed by platelet aggregation test.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    [VIRTUAL] PLATELET AGGREGATION TEST IN PATIENTS WHO RECEIVED GASTRIC ESD UNDER CONTINUOUS ANTIPLATELET AGENTS (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_230;    
    Aims & Between April 2013 and March 2019, a total of 75 cases were performed gastric ESD and assessed by the aggregometer (PRP313 M, TAIYO Inc.) before procedures under continuous antiplatelet agents such as thienopyridine, aspirin, or cilostazol. The levels of platelet aggregometry is low in the cases taking thienopyridine or dual antiplatelet therapy, and the risk of post-ESD bleeding in patients under continuous antiplatelet agents might be assessed by platelet aggregation test.
  • ||||||||||  pentoxifylline / Generic mfg., cilostazol / Generic mfg., milrinone / Generic mfg.
    Review, Journal:  Cyclic nucleotide phosphodiesterase inhibitors: possible therapeutic drugs for female fertility regulation. (Pubmed Central) -  Jul 15, 2020   
    The PDEs inhibitors are used as powerful experimental tools to demonstrate cyclic nucleotide mediated changes in ovarian functions and thereby fertility. Indeed, non-hormonal nature and reversible effects of nonspecific as well as specific PDE inhibitors hold promise for the development of novel therapeutic drugs for female fertility regulation.
  • ||||||||||  aspirin / Generic mfg., Pletal (cilostazol) / Otsuka
    Clinical, Journal:  Thromboangiitis obliterans: Aggressive angioplasty provides a potential solution (randomized pilot study). (Pubmed Central) -  Jun 23, 2020   
    The mean ankle-brachial index significantly improved from 0.54 ± 0.14 preoperatively to 0.82 ± 0.08 at final follow-up (p < 0.01). The endovascular therapy should be considered as an effective, safe, minimally invasive method in the light of the promising results after a modification of the standard technique.
  • ||||||||||  paclitaxel / Generic mfg.
    Clinical, Journal:  Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement. (Pubmed Central) -  Jun 18, 2020   
    In multivariate analysis, vessel calcification (adjusted HR 1.718, 95% CI 1.035 to 2.851, p=0.036) was significantly correlated with the occurrence of ISR, along with lesion length (adjusted HR 1.041, 95% CI 1.013 to 1.070, p=0.003), and cilostazol administration (adjusted HR 0.476, 95% CI 0.259 to 0.876, p=0.017). This study suggested that bilateral vessel wall calcification was an independent risk factor for ISR in complex femoropopliteal lesions after Zilver PTX DCS placement, along with lesion length; cilostazol administration had a protective effect.